KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic : Expert Consensus Statement
The coronavirus disease 2019 (COVID-19) pandemic has reduced the ability to prevent or control chronic disease due to the concerns about safety in accessing health care. Inflammatory bowel disease (IBD) is a chronic condition requiring long- term sustained treatment, which is difficult in the current panedemic situation. The Korean Association for the Study of Intestinal Diseases (KASID) has developed an expert consensus statement on the clinical practice management of adult inflammatory bowel disease during the COVID-19 pandemic. This expert consensus statement is based on guidelines and clinical reports from several countries around the world. It provides recommendations to deal with the risk of COVID-19 and medication use in IBD patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and emphasizes the importance of right treatment approach to avoid worsening of the disease condition in IBD patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi - 78(2021), 2 vom: 25. Aug., Seite 105-116 |
| Sprache: |
Koreanisch |
|---|
| Beteiligte Personen: |
Park, Yong Eun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 18.10.2021 Date Revised 18.10.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.4166/kjg.2021.112 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329895362 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329895362 | ||
| 003 | DE-627 | ||
| 005 | 20231225210120.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||kor c | ||
| 024 | 7 | |a 10.4166/kjg.2021.112 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1099.xml |
| 035 | |a (DE-627)NLM329895362 | ||
| 035 | |a (NLM)34446633 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a kor | ||
| 100 | 1 | |a Park, Yong Eun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic |b Expert Consensus Statement |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.10.2021 | ||
| 500 | |a Date Revised 18.10.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The coronavirus disease 2019 (COVID-19) pandemic has reduced the ability to prevent or control chronic disease due to the concerns about safety in accessing health care. Inflammatory bowel disease (IBD) is a chronic condition requiring long- term sustained treatment, which is difficult in the current panedemic situation. The Korean Association for the Study of Intestinal Diseases (KASID) has developed an expert consensus statement on the clinical practice management of adult inflammatory bowel disease during the COVID-19 pandemic. This expert consensus statement is based on guidelines and clinical reports from several countries around the world. It provides recommendations to deal with the risk of COVID-19 and medication use in IBD patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and emphasizes the importance of right treatment approach to avoid worsening of the disease condition in IBD patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Disease management | |
| 650 | 4 | |a Inflammatory bowel diseases | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Lee, Yoo Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Ji Young |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Hyun Joo |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Duk Hwan |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Young Joo |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Byung Chang |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jae Gon |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Hee Chan |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Miyoung |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Seong-Eun |e verfasserin |4 aut | |
| 700 | 1 | |a Myung, Seung-Jae |e verfasserin |4 aut | |
| 700 | 0 | |a Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi |d 2003 |g 78(2021), 2 vom: 25. Aug., Seite 105-116 |w (DE-627)NLM14272808X |x 2233-6869 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2021 |g number:2 |g day:25 |g month:08 |g pages:105-116 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4166/kjg.2021.112 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 78 |j 2021 |e 2 |b 25 |c 08 |h 105-116 | ||